	US 11,787,866 B2
	Anti-CD25 antibody agents
Anne Goubier, Hertfordshire (GB); Beatriz Goyenechea Corzo, Hertfordshire (GB); Josephine Salimu, Hertfordshire (GB); Kevin Moulder, Hertfordshire (GB); Pascal Merchiers, Hertfordshire (GB); Mark Brown, Hertfordshire (GB); Sergio Quezada, London (GB); James Geoghegan, Lyme, NH (US); and Bianka Prinz, Lebanon, NH (US)
Assigned to Tusk Therapeutics Ltd., Hertfordshire (GB); and Cancer Research Technology Limited, London (GB)
Filed by Tusk Therapeutics Ltd., Hertfordshire (GB); and Cancer Research Technology Limited, London (GB)
Filed on Feb. 5, 2020, as Appl. No. 16/782,461.
Application 16/782,461 is a continuation of application No. 16/352,709, filed on Mar. 13, 2019, granted, now 10,752,691.
Claims priority of provisional application 62/642,232, filed on Mar. 13, 2018.
Claims priority of provisional application 62/642,243, filed on Mar. 13, 2018.
Claims priority of provisional application 62/642,248, filed on Mar. 13, 2018.
Claims priority of provisional application 62/642,230, filed on Mar. 13, 2018.
Claims priority of provisional application 62/642,218, filed on Mar. 13, 2018.
Claims priority of application No. 1804027 (GB), filed on Mar. 13, 2018; application No. 1804028 (GB), filed on Mar. 13, 2018; application No. 1804029 (GB), filed on Mar. 13, 2018; and application No. PCT/EP2018/056312 (WO), filed on Mar. 13, 2018.
Prior Publication US 2021/0009699 A1, Jan. 14, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61P 35/02 (2006.01); A61P 35/00 (2006.01); A61K 39/395 (2006.01); C07K 14/55 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01); C12N 15/85 (2006.01)

CPC C07K 16/2866 (2013.01) [A61K 39/39533 (2013.01); A61K 39/39541 (2013.01); A61K 39/39558 (2013.01); A61K 39/39566 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 14/55 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C12N 15/85 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/20 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/32 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/40 (2013.01); C07K 2317/41 (2013.01); C07K 2317/52 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/569 (2013.01); C07K 2317/60 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C12N 2015/8518 (2013.01)]

11 Claims

1. A composition comprising an anti-CD25 antibody or antigen-binding fragment thereof, comprising:

a) aCD25-a-646-HCDR3 amino acid sequence (SEQ ID NO: 4) as variable heavy chain complementarity determining region 3;

b) a variable heavy chain complementarity determining region 1 (HCDR1) selected from the group consisting of FTFASYGMH (SEQ ID NO: 10) and FTFPSYGMH (SEQ ID NO: 11);

c) a variable heavy chain complementarity determining region 2 (HCDR2) selected from the group consisting of VIWYDASTKYYADSVKG (SEQ ID NO: 12), VIWYDAINKYYADSVKG (SEQ ID NO: 13), VIWYDAVNKYYADSVKG (SEQ ID NO: 14), and VIWYDALNKYYADSVKG (SEQ ID NO: 15);

d) aCD25-a-646-LCDR1 amino acid sequence (SEQ ID NO: 6) as variable light chain complementarity determining region 1;

e) aCD25-a-646-LCDR2 amino acid sequence (SEQ ID NO: 7) as variable light chain complementarity determining region 2; and

f) aCD25-a-646-LCDR3 amino acid sequence (SEQ ID NO: 8) as variable light chain complementarity determining region 3; and

a pharmaceutically acceptable carrier or excipient.